SCHEDULE 13G: Frazier Life Sciences Funds Disclose Significant Stake in Aura Biosciences, Exceeding 9% Ownership
Beneficial Ownership Report
Frazier Life Sciences and its affiliated funds have filed a Schedule 13G, revealing a collective beneficial ownership of 6,315,678 shares, representing 9.9% of Aura Biosciences, Inc.'s common stock.
Summary
- Frazier Life Sciences Public Fund, L.P. (FLSPF) beneficially owns 3,855,722 shares, equating to 6.1% of Aura Biosciences' common stock.
- Frazier Life Sciences Public Overage Fund, L.P. (FLSPOF) beneficially owns 1,137,454 shares, representing 1.8% of the common stock.
- Frazier Life Sciences X, L.P. (FLS X) beneficially owns 159,155 shares, representing 0.3% of the common stock.
- Frazier Life Sciences XI, L.P. (FLS XI) beneficially owns 423,782 shares, representing 0.7% of the common stock.
- Frazier Life Sciences XII, L.P. (FLS XII) beneficially owns 739,565 shares, representing 1.2% of the common stock.
- The aggregate beneficial ownership for James N. Topper and Patrick J. Heron, through their roles in the general partners of the Frazier funds, is 6,315,678 shares, or 9.9% of the class.
- Albert Cha and James Brush each beneficially own 4,993,176 shares, or 7.9% of the class, through their shared control over certain Frazier funds.
- Daniel Estes beneficially owns 1,163,347 shares, or 1.9% of the class, through his shared control over specific Frazier funds.
- The reported beneficial ownership includes both directly held common stock and shares issuable upon exercise of pre-funded warrants within 60 days of May 16, 2025.
- The percentage of class calculation is based on 50,268,758 shares outstanding as of May 9, 2025, an additional 11,735,565 shares sold in a public offering on May 16, 2025, and the shares issuable from pre-funded warrants.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective language or forward-looking statements that would indicate a positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
NA
Industry Context
This filing indicates a significant investment by Frazier Life Sciences, a prominent life sciences investment firm, in Aura Biosciences. Such a substantial stake by a specialized fund can signal confidence in the company's long-term prospects within the biotechnology sector, particularly given the recent public offering.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional ownership stake by Frazier Life Sciences may be viewed positively, potentially signaling investor confidence and stability. The recent public offering also impacts the total outstanding shares, which affects per-share metrics.
Key Dates
| Date | Description |
|---|---|
| 2017-07-31 | Date of Power of Attorney filing for James N. Topper and Patrick J. Heron. |
| 2021-08-16 | Date of Power of Attorney filing for Albert Cha and James Brush. |
| 2022-04-18 | Date of Power of Attorney filing for Daniel Estes. |
| 2025-05-09 | Date of common stock outstanding count (50,268,758 shares) as reported in Issuer's Form 10-Q. |
| 2025-05-15 | Date of filing of Issuer's Quarterly Report on Form 10-Q. |
| 2025-05-16 | Date of event which requires filing of this statement; also the date of the Issuer's Prospectus Supplement filing for a public offering and the date from which pre-funded warrants are exercisable within 60 days. |
| 2025-05-23 | Date of signing of the Schedule 13G filing and Joint Filing Agreement. |
Keywords
Aura Biosciences, Frazier Life Sciences, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Warrants, Public Offering, Biotechnology, Investment Fund
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.